Vumedi

💨 Where could inhaled insulin fit into pediatric diabetes care? In this episode from Taking Control Of Your Diabetes (TCOYD), pediatric endocrinologist Dr. Jamie Wood joins Drs. Steve Edelman and Jeremy Pettus, MD to break down findings from the INHALE-1 trial and what they could mean for children and adolescents with diabetes. They discuss glycemic outcomes, hypoglycemia, weight, lung function, and treatment satisfaction—along with practical considerations that can make mealtime insulin challenging for young patients, from needle anxiety and pre-bolusing to school, sports, and social situations. With inhaled insulin now approved down to age 6, what role could another insulin delivery option play in pediatric practice? 🎧 Watch or listen to the full TCOYD conversation: https://lnkd.in/g2PvdD5p 🔎 Explore more expert diabetes education from TCOYD on Vumedi: https://lnkd.in/gPwkwDeW #Type1Diabetes #PediatricDiabetes #DiabetesCare #Insulin #Endocrinology #MedicalEducation

🔥 The Nice Shoulder Course is now available in full on Vumedi! Great news for the orthopaedic community: all lectures, live surgeries, and panel discussions from the Nice Shoulder Course can now be streamed completely free of charge. 💡 Stream surgical techniques, expert lectures, and debates anytime, anywhere. 🔗 Access the full course now: https://lnkd.in/egUScSFf

More ways to learn. More physician voices to learn from. 🎧 Welcome to Vumedi, This is Why with Dr. Busti!

Cardiovascular disease remains the leading cause of death worldwide, accounting for nearly one in three deaths. This #WorldHeartDay, we’re recognizing the clinicians and educators working to reduce that burden and looking at how cardiovascular learning is evolving on Vumedi. Over the last six months, some of the strongest growth has been in areas central to earlier risk recognition and disease assessment: 🫀 Understanding cardiovascular risk more broadly. Clinician learning around diabetes and kidney disease grew 40%, with viewing time up 39%, while cholesterol and lipid education remained a major focus. This comes amid updated dyslipidemia guidance and growing recognition of cardiovascular, kidney, and metabolic health as interconnected areas of risk. 🫀Evaluating cardiovascular disease. Within cardiovascular imaging, echocardiography reached 29% more clinicians, with viewing time increasing 85%. 🫀Together, these trends point to growing emphasis on more comprehensive risk assessment and cardiovascular disease evaluation. Thank you to the clinicians and educators who share their expertise, and to those who continue learning on behalf of their patients. #WorldHeartDay #Cardiology #MedicalEducation

Every breath depends on someone who kept learning. In the past year, physicians spent 8,239 hours learning pulmonology on Vumedi. That's like attending more than 340 full medical conferences, without leaving the clinic. This #WorldLungDay, thank you: 🫁 To the pulmonologists, intensivists and primary care physicians who catch lung disease early and keep learning long after training ends. 🫁 To the experts who share their cases on Vumedi so other physicians can learn from them. 🫁 To the researchers and innovators building new therapies, devices and diagnostics to improve lung health. 🫁 To our industry and society partners who help get that knowledge to the doctors who need it. A lifetime of lung health starts with a lifetime of learning. Which area of respiratory care do you think needs the most attention right now? #LungHealth #Pulmonology #MedicalEducation

Physician attention is at a premium. Our CRO Dante Gaudio spoke about why when HCPs engage is the angle to watch. His take from #FPW2026 below.

Fierce Pharma Week did not disappoint. ⚡ From sponsoring the HCP Engagement Track to connecting with so many bright minds across the industry, the energy all week was unmatched. A major highlight for the Vumedi team was our luncheon on "The 52-Minute Doctor." We had a standing-room-only crowd exploring how physician learning habits are evolving alongside AI and an unprecedented wave of new therapies, devices, and procedures. When you get a room full of leaders discussing how to meet doctors along their journey to clinical conviction, the ideas just fly. A huge thank you to the organizers and speakers who made the event so valuable — and to the incredible teams from CMI Media Group, Merck, Astellas Pharma, Eli Lilly and Company, Publicis Health, Incyte, and so many others who took time to sit down with us, join our luncheon, and share where their brands are heading next. Our team left inspired, energized, and ready for what’s next. #FPW2026 #LifeSciences #HealthcareMarketing #PhysicianEngagement

Out of everyone who could theoretically be your audience, which HCPs are ready to adopt a new treatment or medical device, right now? That question used to be a guess. But new tools, including AI, are surfacing signals that didn't exist a year ago — not just where physicians are, but what they're doing, and what that behavior says about intent. A lot of HCP intent behavior happens on our Vumedi platform as physicians seek peer-to-peer expertise and learn about new therapies. We're not inferring from audience segments or broad impressions data. We can see who's actively asking about a specific treatment, who's watching related content, who is researching a competitor, who keeps coming back, when and for how long. Why are these signals important? They help you narrow your audience in real time. Say your treatment targets a specialty with ~30k physicians across a region. Reach data tells you all of them are technically in scope. But engagement and intent signals tell you which ~200 physicians are showing real interest right now. And that’s the list your media plan gets built around. The physician journey has changed. Every marketer in this industry has said that by now. Fewer have said what to do about it. We say: don’t just target by reach, target by readiness. Follow the signals physicians are sending as they consult, research, and learn. Be there at the moment they are looking for you. Our team is at Fierce Pharma Week with data on these signals. It’s fascinating how these new data points can help brands stop guessing and start knowing who is ready to adopt. Come find us on the HCP Engagement Track (Terrace Ballroom II) if you’d like to learn more about what we see in the data. #HCPEngagement #PharmaMarketing #MedicalEducation #FPW2026

Most patients don't present like the guidelines. Treatment decisions rarely have a clean trial to point to. They involve sequencing, timing, a patient who doesn't fit the inclusion criteria, someone not severe enough for a high-efficacy biologic but no longer responding to first-line treatment. Real clinical decisions are full of these nuances. The judgment calls specialists make come from what they've seen work in practice, not just what's been published. We hear this directly from physicians on Vumedi. They tell us that they reach for different tools for clinical decision support: something quick when they need a fast reference answer, and something with more depth like peer experience or trial-adjacent expertise when the decision is unfamiliar or higher-stakes. Ongoing peer-to-peer learning shares that expertise across the physician community. Vumedi has over 100k medical community videos totaling more than 2 million minutes in our library and a proprietary AI layer on top of this deep content to allow physicians to query, summarize, and locate relevant content as they learn. When doctors use the AI tools, they deepen and extend their learning – not shorten it. #ClinicalDecisionMaking #PeerToPeerLearning #HCPMarketing

Come meet our team at Fierce Pharma Week next week! Looking forward to the conversations about how physician education is changing. #FPW2026 #HCPEngagement